Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Allen Cohn

Concepts (195)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colorectal Neoplasms
25
2024
874
2.440
Why?
Antineoplastic Combined Chemotherapy Protocols
31
2021
1998
2.050
Why?
Antibodies, Monoclonal, Humanized
27
2024
992
1.540
Why?
ras Proteins
7
2019
148
1.500
Why?
Antibodies, Monoclonal
16
2018
1512
1.230
Why?
Phenylurea Compounds
10
2024
122
1.220
Why?
Adenocarcinoma
9
2016
927
1.000
Why?
Proto-Oncogene Proteins
5
2015
616
0.730
Why?
Fluorouracil
17
2019
231
0.710
Why?
Camptothecin
12
2019
139
0.670
Why?
Liver Neoplasms
6
2026
776
0.660
Why?
Leucovorin
14
2019
98
0.660
Why?
Quinolines
5
2024
191
0.650
Why?
Organoplatinum Compounds
14
2017
65
0.630
Why?
Disease-Free Survival
14
2017
778
0.610
Why?
Bevacizumab
15
2024
169
0.590
Why?
Endometrial Neoplasms
4
2024
205
0.580
Why?
Biological Therapy
1
2018
30
0.530
Why?
Neoplasms
6
2026
2954
0.510
Why?
Mutation
5
2020
4093
0.490
Why?
Protein Kinase Inhibitors
9
2025
983
0.480
Why?
Biomarkers, Tumor
9
2024
1339
0.470
Why?
Antineoplastic Agents
6
2025
2219
0.460
Why?
Epithelial-Mesenchymal Transition
1
2017
219
0.430
Why?
Aged
42
2026
26432
0.430
Why?
Kaplan-Meier Estimate
12
2018
970
0.410
Why?
Antimetabolites, Antineoplastic
4
2009
108
0.410
Why?
Salvage Therapy
2
2015
166
0.400
Why?
Carcinoma, Hepatocellular
3
2017
370
0.390
Why?
Transforming Growth Factor beta1
1
2014
176
0.390
Why?
Saccharomyces cerevisiae
1
2018
584
0.390
Why?
Neoplasm Metastasis
10
2019
693
0.380
Why?
Gene Expression
1
2018
1463
0.380
Why?
Antineoplastic Agents, Immunological
3
2021
200
0.370
Why?
Aged, 80 and over
23
2018
8391
0.370
Why?
Middle Aged
43
2026
36619
0.360
Why?
Giant Cell Tumor of Tendon Sheath
2
2022
9
0.350
Why?
Pyrimidines
5
2025
532
0.350
Why?
Cholangiocarcinoma
2
2025
110
0.350
Why?
Bile Duct Neoplasms
2
2025
132
0.340
Why?
Cetuximab
7
2019
110
0.310
Why?
Adult
39
2025
41087
0.300
Why?
Pyridines
3
2018
610
0.290
Why?
Receptor, Macrophage Colony-Stimulating Factor
2
2022
12
0.290
Why?
Glutamates
2
2013
66
0.290
Why?
Proto-Oncogene Proteins p21(ras)
5
2015
250
0.290
Why?
Guanine
2
2013
85
0.290
Why?
Double-Blind Method
8
2018
2070
0.290
Why?
Antineoplastic Agents, Phytogenic
2
2007
178
0.280
Why?
Carcinoma, Renal Cell
2
2021
231
0.280
Why?
Female
46
2026
79499
0.260
Why?
Pyrroles
2
2021
222
0.260
Why?
Male
43
2026
73396
0.250
Why?
Stomach Neoplasms
3
2016
128
0.240
Why?
Kidney Neoplasms
2
2021
419
0.240
Why?
Carcinoma, Acinar Cell
1
2026
4
0.240
Why?
Paclitaxel
1
2007
260
0.230
Why?
Yttrium Radioisotopes
1
2026
64
0.230
Why?
Humans
55
2026
146342
0.230
Why?
Circulating Tumor DNA
1
2026
50
0.220
Why?
Neoplasm Recurrence, Local
3
2018
1160
0.220
Why?
Drug-Related Side Effects and Adverse Reactions
3
2018
266
0.220
Why?
Treatment Outcome
18
2026
11821
0.220
Why?
Receptor, Fibroblast Growth Factor, Type 2
2
2025
28
0.220
Why?
Pancreatic Neoplasms
3
2026
944
0.210
Why?
Neoplasm Staging
7
2015
1488
0.200
Why?
Angiogenesis Inhibitors
3
2014
239
0.200
Why?
Deoxycytidine
6
2020
219
0.200
Why?
Early Detection of Cancer
2
2026
506
0.190
Why?
Dose-Response Relationship, Drug
6
2015
2022
0.190
Why?
Rectal Neoplasms
1
2024
160
0.180
Why?
Disease Progression
10
2021
2867
0.180
Why?
Cell-Free Nucleic Acids
1
2022
40
0.180
Why?
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
1
2022
16
0.180
Why?
Drug Administration Schedule
5
2014
790
0.170
Why?
Colonic Neoplasms
1
2024
259
0.170
Why?
Survival Rate
5
2019
2092
0.170
Why?
Esophageal Neoplasms
2
2016
351
0.160
Why?
Gene Expression Regulation, Neoplastic
2
2018
1432
0.160
Why?
Neovascularization, Pathologic
2
2019
287
0.150
Why?
Aminopyridines
2
2021
128
0.150
Why?
Niacinamide
2
2017
103
0.140
Why?
Proto-Oncogene Proteins c-raf
1
2019
46
0.140
Why?
Oncogene Proteins, Fusion
1
2020
213
0.140
Why?
Vascular Endothelial Growth Factor D
1
2018
13
0.140
Why?
Immunity
1
2018
141
0.130
Why?
Esophagogastric Junction
2
2016
54
0.120
Why?
Anilides
1
2017
83
0.120
Why?
Gonanes
1
2016
23
0.120
Why?
Proportional Hazards Models
3
2014
1331
0.110
Why?
Giant Cell Tumors
1
2015
4
0.110
Why?
Complement Activation
1
2018
412
0.110
Why?
Pyrazoles
1
2018
517
0.100
Why?
Soft Tissue Neoplasms
1
2015
133
0.100
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2013
31
0.100
Why?
Insulin-Like Growth Factor Binding Proteins
1
2013
26
0.100
Why?
Topoisomerase I Inhibitors
1
2012
20
0.090
Why?
Receptors, IgG
1
2013
77
0.090
Why?
Cisplatin
2
2020
347
0.090
Why?
Heterocyclic Compounds, 4 or More Rings
1
2012
25
0.090
Why?
Pemetrexed
2
2013
40
0.090
Why?
Time Factors
6
2021
7109
0.090
Why?
ErbB Receptors
2
2015
636
0.090
Why?
Follow-Up Studies
4
2019
5439
0.090
Why?
Neoplasm Proteins
1
2014
444
0.080
Why?
Vascular Endothelial Growth Factor A
3
2021
545
0.080
Why?
Treatment Failure
2
2013
361
0.080
Why?
DNA, Neoplasm
1
2011
160
0.080
Why?
Real-Time Polymerase Chain Reaction
1
2011
334
0.080
Why?
Drug Resistance, Neoplasm
3
2025
893
0.070
Why?
Capecitabine
4
2013
56
0.070
Why?
Carmustine
1
2008
52
0.070
Why?
Genotype
1
2013
1879
0.070
Why?
Azacitidine
1
2009
168
0.070
Why?
Tumor Burden
2
2022
326
0.060
Why?
Polyethylene Glycols
1
2012
650
0.060
Why?
Prognosis
3
2026
4351
0.060
Why?
Blood Cell Count
1
2007
56
0.060
Why?
Cohort Studies
3
2014
6077
0.060
Why?
Half-Life
1
2007
157
0.060
Why?
Vitamin B 12
1
2008
140
0.060
Why?
Myelodysplastic Syndromes
1
2009
170
0.060
Why?
Folic Acid
1
2008
197
0.060
Why?
Area Under Curve
1
2007
335
0.060
Why?
Adolescent
6
2024
22557
0.060
Why?
Dexamethasone
1
2008
368
0.060
Why?
Pancreaticoduodenectomy
1
2026
149
0.050
Why?
Carcinoma
1
2006
225
0.050
Why?
Carcinoma, Non-Small-Cell Lung
1
2013
1195
0.050
Why?
Glioma
1
2008
425
0.050
Why?
Young Adult
4
2014
14330
0.050
Why?
Taxoids
2
2013
115
0.050
Why?
Longitudinal Studies
2
2026
3017
0.050
Why?
Apoptosis
1
2011
2439
0.050
Why?
Cytarabine
1
2002
66
0.040
Why?
Response Evaluation Criteria in Solid Tumors
1
2022
21
0.040
Why?
United States
5
2021
16136
0.040
Why?
Prospective Studies
2
2012
8123
0.040
Why?
Meningeal Neoplasms
1
2002
95
0.040
Why?
Europe
1
2021
421
0.040
Why?
Lung Neoplasms
1
2013
2675
0.040
Why?
Infusions, Intravenous
2
2013
432
0.040
Why?
Microsatellite Instability
1
2020
57
0.040
Why?
Translocation, Genetic
1
2020
127
0.040
Why?
Brain Neoplasms
1
2008
1325
0.040
Why?
Janus Kinase 1
1
2018
26
0.030
Why?
Janus Kinase 2
1
2018
31
0.030
Why?
Case-Control Studies
1
2026
3647
0.030
Why?
Receptors, Vascular Endothelial Growth Factor
1
2018
109
0.030
Why?
DNA Methylation
1
2022
725
0.030
Why?
Liver
1
2026
1864
0.030
Why?
RNA
1
2024
926
0.030
Why?
Nitriles
1
2018
212
0.030
Why?
Molecular Targeted Therapy
1
2020
447
0.030
Why?
Mice
1
2014
18297
0.030
Why?
Survival Analysis
3
2008
1378
0.030
Why?
Registries
2
2016
2400
0.030
Why?
Phosphoramide Mustards
1
2014
3
0.030
Why?
Nitroimidazoles
1
2014
16
0.030
Why?
Recurrence
1
2018
1133
0.030
Why?
Drug Discovery
1
2015
154
0.030
Why?
Tendons
1
2015
136
0.030
Why?
Platinum Compounds
1
2013
10
0.030
Why?
Research Design
1
2020
1143
0.030
Why?
Crystallography, X-Ray
1
2015
477
0.020
Why?
Lymphatic Metastasis
1
2015
335
0.020
Why?
Dasatinib
1
2013
58
0.020
Why?
Maximum Tolerated Dose
1
2013
217
0.020
Why?
src-Family Kinases
1
2013
93
0.020
Why?
Palliative Care
1
2002
1032
0.020
Why?
Thiazoles
1
2013
139
0.020
Why?
Injections, Intravenous
1
2013
197
0.020
Why?
Indazoles
1
2013
86
0.020
Why?
Caspase 3
1
2013
240
0.020
Why?
Canada
1
2013
432
0.020
Why?
Animals
1
2014
38106
0.020
Why?
Imidazoles
1
2013
245
0.020
Why?
Multivariate Analysis
1
2014
1543
0.020
Why?
Liver Transplantation
1
2016
751
0.020
Why?
Breast Neoplasms
1
2002
2418
0.020
Why?
Magnetic Resonance Imaging
1
2022
3926
0.020
Why?
Southwestern United States
1
2008
93
0.020
Why?
Endpoint Determination
1
2009
84
0.020
Why?
Radiotherapy, Conformal
1
2008
75
0.020
Why?
Statistics, Nonparametric
1
2008
426
0.020
Why?
Exanthema
1
2006
86
0.010
Why?
Blood Transfusion
1
2009
394
0.010
Why?
Severity of Illness Index
1
2013
2921
0.010
Why?
Combined Modality Therapy
1
2008
1271
0.010
Why?
Multicenter Studies as Topic
1
2005
417
0.010
Why?
Injections, Spinal
1
2002
120
0.010
Why?
Delayed-Action Preparations
1
2002
192
0.010
Why?
Consumer Product Safety
1
2002
80
0.010
Why?
Administration, Oral
1
2002
872
0.010
Why?
Quality of Life
1
2008
3200
0.010
Why?
Cohn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)